相关实验视频

Updated: May 11, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

抑制FGFR4增加了卵巢癌中帕克利塔塞尔诱导的细胞死亡

Renya Zeng¹, Xingcheng Chen², Yuanhong Chen²

¹Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.; Department of Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China..

International immunopharmacology

|April 17, 2025

概括

向纤维细胞生长因子受体4 (FGFR4) 可以克服在上皮卵巢癌 (EOC) 中的帕克利塔塞尔耐药性. 抑制FGFR4使EOC细胞对帕克利塔塞尔敏感,为改善患者结果提供了一种新的治疗策略.

科学领域:

妇科瘤学妇科瘤学
癌症生物学癌症生物学
药物耐药性机制药物耐药性机制

背景情况:

表皮卵巢癌 (EOC) 是一种具有高复发率的致命恶性瘤,通常是由于对像帕克利塔塞尔这样的化疗疗法的耐药性.
了解帕克利塔塞尔耐药性的机制对于开发有效的治疗方法至关重要.

研究的目的:

确定EOC中帕克利塔克塞尔耐药性的关键调节者.
研究纤维细胞生长因子受体4 (FGFR4) 在调解帕克利塔塞尔耐药性的作用.
探索FGFR4作为一种潜在的治疗点,以克服EOC的耐药性.

主要方法:

利用基于Phos-tag的幕来识别帕克利塔克塞尔耐药性调节剂,专注于FGFR4.
采用了亡测定,西部抹杀和定量PCR来阐明FGFR4的功能作用和下游信号通路.
通过体外和体内研究验证的发现,包括针对药物协同作用的免疫光染色.

主要成果:

在体外和体内,FGFR4的减少抑制了EOC细胞的增殖,迁移和瘤生长.
抑制FGFR4会使EOC细胞对帕克利塔塞尔敏感,而过度表达会产生抗药性.
通过MEK-ERK-RSK通路,FGFR4通过上调抗亡蛋白Bcl-xL来促进帕克利塔塞尔耐药性.

结论:

FGFR4是EOC中帕克利塔克塞尔耐药性的关键调解者.
准FGFR4或其下游MEK-ERK-RSK/Bcl-xL信号,是一个有前途的战略,以重新敏感化EOC对帕克利塔塞尔.
抑制FGFR4提供了一种新的治疗方法,以改善EOC患者的治疗结果.

关键词:

在 Bcl-xL 中.卵巢上皮癌是卵巢癌的表皮癌.在FGFR4中.帕克利塔克塞尔的耐药性纳税人就是纳税人.

更多相关视频

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...